Title : A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.

Pub. Date : 2021 Sep 1

PMID : 34190716






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 There was no statistically significant difference in ERK activation compared with placebo (P=0.45); however, ERK activation was reduced 74% compared with pretreatment biopsy with vandetinib treatment (P=0.005) without a significant reduction in the placebo group (-29%, P=0.55). vandetanib EPH receptor B2 Homo sapiens
2 In accordance with the investigational hypothesis, there was a nonsignificant trend with vandetanib treatment of reduction in p-ERK and increased effects in Ret expressing tumors. vandetanib EPH receptor B2 Homo sapiens